EU Grants

The goal of AARC2 is to design an AAI framework to develop an interoperable AAI to enable researchers to access the whole research and infrastructure service portfolio with one login.

CINECA’s vision is a federated cloud enabled infrastructure making population scale genomic and biomolecular data accessible across international borders, accelerating research, and improving the health of individuals across continents. CINECA will leverage international investment in human cohort studies from Europe, Canada, and Africa to deliver a paradigm shift of federated research and clinical applications.

ConcePTION will build an ecosystem for better monitoring and communicating of medication safety in pregnancy and lactation: validated and regulatory endorsed workflows for fast, optimised evidence generation.

The CY-Biobank project revolves around the upgrading of the existing Biobank of the University of Cyprus, to a Center of Excellence in Biobanking and Biomedical Research, adapting European standards of operation in collaboration with the Advanced Partners. This medical research infrastructure will then serve the foundation for developing the Cyprus human genome project and other genomics/genetics projects for diseases with Mendelian inheritance as well as complex disorders of multifactorial character that impact modern societies.

The European Joint Programme on Rare Diseases brings over 130 institutions from 35 countries to create a comprehensive, sustainable ecosystem allowing a virtuous circle between research, care and medical innovation.

Its aims are to improve the integration, the efficacy, the production and the social impact of research on RD through the development, demonstration and promotion of Europe/world-wide sharing of research and clinical data, materials, processes, knowledge and know-how; and to implement and further develop an efficient model of financial support for all types of research on RD (fundamental, clinical, epidemiological, social, economic, health service) coupled with accelerated exploitation of research results for benefit of patients.

EOSC-Life brings together the 13 Biological and Medical ESFRI research infrastructures (BMS RIs) to create an open collaborative space for digital biology. The goal of the EOSC-Life project is to make sure that life-scientists can find, access and integrate life-science data for analysis and reuse in academic and industrial research.

EUCAN-Connect will enable large-scale integrated cohort data analysis for personalized and preventive healthcare across EU and Canada. EUCAN-Connect platform and collaborations will be coordinated through BBMRI-ERIC (EU) and Maelstrom Research (Canada) to sustain long-term benefits to science and citizens worldwide.

EPTRI is aimed at harnessing the research and services for the development of medicines for children as well as identifying gaps in paediatric medicines research preventing efficient use of research technologies across pertinent medicine research fields, from discovery and preclinical phase, all the way to ameliorate the therapeutic use of medicines in clinical practice. Sharing understanding of patients’ needs and concerted efforts in critical areas of research will end in further enhancing the health of children and will also have a positive impact on European competitiveness in the pharmaceutical sector.

The overarching goal of RItrain is to identify the competency requirements for the leadership of European research infrastructures (RI) and design a training programme to fulfil these requirements. Our highest priority is those professionals who are already working in research infrastructures, including directors, coordinators, senior project managers, legal representatives, heads of Finance and HR, and heads of communication.

Molecular in vitro diagnostics and biomedical research have allowed great progress in personalised medicine but further progress is limited by insufficient guidelines for pre-analytical workflow steps (sample collection, preservation, etc.) as well as by insufficient quality assurance of diagnostic practice. This allows using compromised patients’ samples with post collection changes in cellular and extra-cellular biomolecules’ profiles thus often making diagnostic test results unreliable or even impossible.

Thus, SPIDA4P aims to generate and implement a comprehensive portfolio of 22 pan-European pre-analytical CEN/TS and ISO/IS, addressing the important pre-analytical workflows applied to personalized medicine.